1 / 7

SATURN: Objective

The SATURN trial examined the impact of rosuvastatin (40 mg) versus atorvastatin (80 mg) on coronary atherosclerosis progression in 1385 symptomatic CAD patients. Participants with LDL-C levels above 80 mg/dL were randomized to receive either medication. Intravascular ultrasound (IVUS) was used to assess changes in atheroma volume over 24 months. Results indicated a median change in percent atheroma volume, with significant findings for both treatments, highlighting LDL-C's role in atherosclerosis progression.

nita
Download Presentation

SATURN: Objective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progressionof coronary atherosclerosis assessed by intravascular ultrasound.

  2. SATURN; Study Design 1385 patients with symptomatic CAD (angiographic stenosis >20%) LDL-C with (>80 mg/dL) or without (>100 mg/dL) statin use last 4 weeks Rosuvastatin 40 mg (n =694) Atorva 40 mg Atorvastatin 80 mg (n=691) Rosuva 20 mg Visit: Week: 1 –4 2 –2 3 0 4 13 5 26 6 39 7 52 8 65 9 78 10 91 11 104 Safety IVUS Lipids Lipids Safety LipidsSafety Safety Safety LipidsSafety Safety LipidsSafety IVUS Lipids Safety Screening Period Randomization Period

  3. SATURN Trial: Flow of Patients 4255 patients screened and 1578 patients treated at centers in North America, Europe, South America and Australia Treatment for 2 weeks with atorvastatin 40 mg or rosuvastatin 20 mg for 2 weeks to achieve LDL-C <116 mg/dL 24 monthstreatment Rosuvastatin 40 mg (n=694) Atorvastatin 80 mg (n=691) 346 (25%) patients withdrew or did not have an evaluable final IVUS Follow-up IVUS of originally imaged “target” vessel (n=1039)

  4. SATURN: Clinical Characteristics

  5. SATURN: Time-Weighted Lipid Levels and hsCRP

  6. SATURN: Primary IVUS Efficacy Parameter Median Change Percent Atheroma Volume P=0.17† Change Percent Atheroma Volume -0.99 -1.22 P<0.001* P<0.001*

  7. LDL-C and Disease Progression Median Change Percent Atheroma Volume

More Related